secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0000950170-24-034688
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics reports Q4/FY2023 results; cash $128.6M funds through late 2025
--------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities at $128.6M as of Dec 31, 2023; expected to fund through late 2025.
- Collaboration revenue $2.1M in Q4 and $7.9M for FY2023, up from $1.4M and $5.7M prior year.
- Loss from operations improved to $19.8M (Q4) and $76.2M (FY2023) vs $21.0M and $90.3M.
- BDC-1001 Phase 2 advancing in five HER2-positive tumor cohorts; 29% ORR at RP2D reported at ESMO 2023.
- BDC-3042 Phase 1 cleared three dose levels without DLT; now enrolling fourth cohort.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017024034688/0000950170-24-034688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017024034688/bolt-20240321.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer